Emirates Drug Establishment Reviews Key Achievements And Approves Strategic Roadmap For Future Innovation

The Emirates Drug Establishment (EDE) Board of Directors recently evaluated the progress of its 2024–2026 strategy. They reviewed key achievements and set strategic priorities to enhance innovation and sustainability in the medical and pharmaceutical sectors. This meeting, chaired by Saeed Mubarak Al Hajeri, Minister of State, also included Dr. Maha Taysir Barakat, Vice Chairwoman; Dr. Fatima Mohammed Hilal Al Kaabi, EDE Director-General; and other board members.

Al Hajeri praised Dr. Thani bin Ahmed Al Zeyoudi, Minister of Foreign Trade, for his strategic vision during his time as Board Chair. He acknowledged the efforts to strengthen the Establishment's regulatory foundations and elevate its role in pharmaceutical innovation. Al Hajeri also commended the board members and EDE teams for their dedication to achieving national health objectives.

Dr. Fatima Al Kaabi highlighted the steady progress in implementing strategic plans to achieve EDE's ambitious vision. She noted the modernisation of organisational structures and expanded research collaborations, which positively impact community well-being and sustainable economic growth. The strategy includes integrating artificial intelligence into drug discovery and adopting sustainable manufacturing standards.

The Board discussed developmental priorities to enhance the national pharmaceutical sector's readiness. They reviewed phased objectives within EDE's strategy, focusing on completing service transfers from ministries and providing regulatory services to stakeholders. These efforts aim to build an integrated service ecosystem under EDE's umbrella.

The Board examined mechanisms to expedite marketing approvals for medicines by directly assessing scientific dossiers without waiting for reference-country approvals. This approach ensures rapid availability of innovative therapeutic solutions, reinforcing the UAE's position as a leading hub for advanced healthcare delivery aligned with international quality standards.

Aligned with EDE’s vision for a flexible regulatory environment driven by innovation, these measures will facilitate access to modern therapies efficiently and sustainably. The Board emphasised adopting advanced technologies like artificial intelligence to enhance manufacturing processes, accelerate innovation, and deliver sustainable health solutions effectively.

Community Engagement

The launch of Contact Centre 80033784 (800Edrug) was approved by the Board as a central communication platform between customers and EDE. This centre will handle inquiries, feedback, and suggestions, promoting faster access to reliable information while enhancing transparency between the community and EDE.

Al Hajeri expressed pride in consolidating the UAE’s position as a trusted hub for pharmaceutical innovation. He highlighted efforts to expand local manufacturing capacities, support research ecosystems, and adhere to international standards. The Establishment aims to develop innovative solutions through strategic partnerships in pharmaceutical innovation and research.

The Board reiterated its commitment to driving leadership within medical industries while ensuring future readiness. By fostering effective partnerships in research and development, EDE continues contributing significantly towards achieving national objectives in health sectors.

With inputs from WAM